165 related articles for article (PubMed ID: 37560390)
1. New Psychoactive Substances: A Potential Threat to Developing Countries.
Hasan M; Sarker SA
Addict Health; 2023 Apr; 15(2):136-143. PubMed ID: 37560390
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Google Trends to monitor new psychoactive substance. Is there an added value?
Batistic FK; Rhumorbarbe D; Lefrancois E; Tettey J; Raithelhuber M; Rossy Q; Morelato M
Forensic Sci Int; 2021 Jul; 326():110918. PubMed ID: 34325112
[TBL] [Abstract][Full Text] [Related]
3. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
4. The effects of the COVID-19 pandemic on the use of the performance-enhancing drugs.
Negro F; Di Trana A; Marinelli S
Acta Biomed; 2022 Jan; 92(6):e2021401. PubMed ID: 35075058
[TBL] [Abstract][Full Text] [Related]
5. Taking the cat-and-mouse game to the next level: different perspectives on the introduction of the German New Psychoactive Substances Act.
Kühnl R; Aydin D; Horn S; Olderbak S; Verthein U; Kraus L
Harm Reduct J; 2022 Nov; 19(1):122. PubMed ID: 36329471
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
[TBL] [Abstract][Full Text] [Related]
7. Mapping novel psychoactive substances policy in the EU: The case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden.
Neicun J; Steenhuizen M; van Kessel R; Yang JC; Negri A; Czabanowska K; Corazza O; Roman-Urrestarazu A
PLoS One; 2019; 14(6):e0218011. PubMed ID: 31242225
[TBL] [Abstract][Full Text] [Related]
8. A review of synthetic cathinones emerging in recent years (2019-2022).
Kuropka P; Zawadzki M; Szpot P
Forensic Toxicol; 2023; 41(1):25-46. PubMed ID: 36124107
[TBL] [Abstract][Full Text] [Related]
9. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
Grafinger KE; Bernhard W; Weinmann W
Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
[TBL] [Abstract][Full Text] [Related]
10. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
Napoletano S; Basile G; Lo Faro AF; Negro F
Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
[TBL] [Abstract][Full Text] [Related]
11. Monitoring new psychoactive substances: Exploring the contribution of an online discussion forum.
Rhumorbarbe D; Morelato M; Staehli L; Roux C; Jaquet-Chiffelle DO; Rossy Q; Esseiva P
Int J Drug Policy; 2019 Nov; 73():273-280. PubMed ID: 30967328
[TBL] [Abstract][Full Text] [Related]
12. New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.
Zaami S
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9681-9690. PubMed ID: 31799633
[TBL] [Abstract][Full Text] [Related]
13. Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants.
Miliano C; Serpelloni G; Rimondo C; Mereu M; Marti M; De Luca MA
Front Neurosci; 2016; 10():153. PubMed ID: 27147945
[TBL] [Abstract][Full Text] [Related]
14. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
[No Abstract] [Full Text] [Related]
15. New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries.
Kurcevič E; Lines R
Harm Reduct J; 2020 Nov; 17(1):94. PubMed ID: 33256747
[TBL] [Abstract][Full Text] [Related]
16. International snapshot of new psychoactive substance use: Case study of eight countries over the 2019/2020 new year period.
Bade R; White JM; Chen J; Baz-Lomba JA; Been F; Bijlsma L; Burgard DA; Castiglioni S; Salgueiro-Gonzalez N; Celma A; Chappell A; Emke E; Steenbeek R; Wang D; Zuccato E; Gerber C
Water Res; 2021 Apr; 193():116891. PubMed ID: 33582495
[TBL] [Abstract][Full Text] [Related]
17. Comparison of illegal drug use pattern in Taiwan and Korea from 2006 to 2014.
Feng LY; Yu WJ; Chang WT; Han E; Chung H; Li JH
Subst Abuse Treat Prev Policy; 2016 Sep; 11(1):34. PubMed ID: 27663984
[TBL] [Abstract][Full Text] [Related]
18. The rise of new psychoactive substances and psychiatric implications: A wide-ranging, multifaceted challenge that needs far-reaching common legislative strategies.
Rinaldi R; Bersani G; Marinelli E; Zaami S
Hum Psychopharmacol; 2020 May; 35(3):e2727. PubMed ID: 32144953
[TBL] [Abstract][Full Text] [Related]
19. New psychoactive substances in Taiwan: challenges and strategies.
Feng LY; Li JH
Curr Opin Psychiatry; 2020 Jul; 33(4):306-311. PubMed ID: 32167950
[TBL] [Abstract][Full Text] [Related]
20. New psychoactive substances in Turkey: Narcotics cases assessed by the Council of Forensic Medicine between 2016 and 2017 in Ankara, Turkey.
Göl E; Çok I
Forensic Sci Int; 2019 Jan; 294():113-123. PubMed ID: 30502695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
